SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Guindo Chirfi | EVP, Access, Policy & Comms | 2026-08-13 | Open-market sell | 10000 | $1.4M |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | 2026-08-12 | Open-market sell | 11099 | $1.5M |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | 2026-08-12 | Open-market sell | 600 | $79K |
| Zachary Jennifer | EVP, General Counsel | 2026-08-12 | Option exercise | 41494 | $4.9M |
| Zachary Jennifer | EVP, General Counsel | 2026-08-12 | Option exercise | 13433 | $1.1M |
| Zachary Jennifer | EVP, General Counsel | 2026-08-12 | Open-market sell | 80315 | $10.7M |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | 2026-08-11 | Open-market sell | 7410 | $973K |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | 2026-08-11 | Open-market sell | 5427 | $718K |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | 2026-08-10 | Open-market sell | 20784 | $2.7M |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | 2026-08-06 | Open-market sell | 805 | $105K |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | 2026-08-06 | Open-market sell | 4945 | $644K |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | 2026-08-06 | Open-market sell | 300 | $39K |
| Guindo Chirfi | EVP, Access, Policy & Comms | 2026-08-06 | Open-market sell | 15000 | $2.0M |
| Maraldo David R. | EVP & Pres. MMD | 2026-08-05 | Option exercise | 6311 | $465K |
| Maraldo David R. | EVP & Pres. MMD | 2026-08-05 | Open-market sell | 6311 | $812K |
| Maraldo David R. | EVP & Pres. MMD | 2026-08-05 | Option exercise | 9709 | $846K |
| Maraldo David R. | EVP & Pres. MMD | 2026-08-05 | Open-market sell | 9709 | $1.2M |
| Maraldo David R. | EVP & Pres. MMD | 2026-08-05 | Option exercise | 2686 | $228K |
| Maraldo David R. | EVP & Pres. MMD | 2026-08-05 | Open-market sell | 2686 | $346K |
| Williams David Michael | EVP,Chief Info&Digital Officer | 2026-08-05 | Option exercise | 4600 | $357K |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
Merck's near-term revenue risk has materially worsened, driven by accelerating exclusivity losses across Bridion, Januvia/Janumet, and Keytruda, compounded by the collapse of China Gardasil demand with no recovery expected in 2026. Keytruda concentration has risen to 49% of revenue while its biosimilar timeline has pulled forward to 2028-2029, and new government pricing constraints — including an MFN Agreement with direct-to-patient pricing and Medicaid discounts — further compress the pricing environment across current and future launches.
7 company-specific · 1 common-mode
China Gardasil sales collapsed from expected decline to actual significant decline with no material recovery expected in 2026, materially worsening revenue risk.
Item 1A. Risk Factors. Summary Risk Factors The Company is subject to a number of risks that if realized could materially adversely affect its business, results of operations, cash flows, financial…
Newly disclosed material revenue losses: Bridion U.S. exclusivity moved from 2026 to July 2026 with expected discontinuation by end-2026; Januvia/Janumet exclusivity losses in May/July 2026 with near-total U.S. sales loss expected; Keytruda biosimilar competition accelerated to 2028-2029. Substantive worsening of competitive timeline and magnitude.
As the Company’s products lose market exclusivity, the Company generally experiences a significant and rapid loss of sales from those products. The Company depends upon patents to provide it with…
New material government price-setting agreements disclosed: MFN Agreement with direct-to-patient program, Medicaid discounts, and most-favored-nation pricing on future launches materially expand pricing constraints.
The Company faces continued pricing pressure with respect to its products in the public and private sectors. The Company faces continued pricing pressure globally and, particularly in mature markets…
New competitive threat: local nine-valent HPV vaccine approved in China June 2025. Combined with continued shipment pause and no material recovery expected in 2026, materially worsens market position.
The Company’s business in China experienced significantly lower sales of Gardasil/Gardasil 9 in 2025 and the Company expects that sales of Gardasil/Gardasil 9 in China will not materially increase…
Keytruda revenue concentration increased 46% to 49%; Gardasil demand in China escalated from "slowing" to "materially lower"; new risks added (IRA pricing, biosimilars, Qlex utilization).
Key products generate a significant amount of the Company’s profits and cash flows, and any events that adversely affect the markets for its leading products could have a material adverse effect on…
New disclosure of MFN Agreement risk: products may not launch or face delays in MFN Countries, with potential adverse actions. Substantive new regulatory constraint.
Unfavorable or uncertain economic conditions, together with cost-reduction measures being taken by the U.S. and other countries, could negatively affect the Company’s operating results. The…
Company disclosed multi-year SAP system upgrade, introducing material implementation and cybersecurity risks during critical enterprise system modernization.
Risks Related to Technology The Company is increasingly dependent on sophisticated software applications and computing infrastructure, including the use of cloud-based applications and environments.…
Added specific regulatory references (EU AI Act, NIS2) and new risk of unauthorized open-source/generative AI use by employees causing IP leakage or violations.
The Company is increasing its use of artificial intelligence (AI) systems to automate processes, analyze data, and support decision-making, which poses inherent risks. The Company’s growing use of…
This is a clear earnings release for Q2 2026 financial results. The Item 2.02 disclosure incorporates by reference a press release dated August 4, 2026, announcing second-quarter 2026 financial results with detailed financial summaries, sales performance by product, expense information, and full-year 2026 guidance. The filing includes GAAP and non-GAAP EPS, revenue figures ($16.6 billion), and product-level performance metrics—all hallmarks of a quarterly earnings disclosure.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Merck's Annual Meeting of Shareholders held on May 26, 2026, filed under Item 5.07. The filing reports voting outcomes on six matters: election of 13 directors, advisory vote on named executive officer compensation, ratification of the independent auditor, and three shareholder proposals. All proposals passed with majority support, and the detailed vote tallies (votes for, against, abstentions, and broker non-votes) are provided for each matter, which is material to investors' understanding of shareholder governance and company direction.
View raw filing on EDGAR →Merck closed a $5.5 billion underwritten public offering of debt securities across seven tranches (Floating Rate Notes, 2028, 2031, 2033, 2036, 2046, and 2056 Notes). While this is a material financing event affecting the company's capital structure and liquidity, it does not fit neatly into the specific taxonomy categories (not M&A, not a dilutive equity issuance, not a restatement or covenant breach). This is a significant debt issuance that would materially affect a reasonable investor's assessment of the registrant's financial position and leverage.
View raw filing on EDGAR →